Twist Bioscience Corp. Hits New 52-Week High of $61.61

Twist Bioscience Corp. has reached a significant milestone by hitting a new 52-week high of USD 61.61 on April 17, 2026. This achievement highlights the company's performance within the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 2,760 million. Over the past year, Twist Bioscience Corp. has demonstrated a performance increase of 19.6%, although this is notably lower than the S&P 500's performance of 34.89% during the same period. The company's financial metrics reveal a challenging landscape, as it currently operates at a loss, reflected in its price-to-earnings ratio, which is not applicable. Additionally, the company has a negative return on equity of -16.79% and a debt-to-equity ratio of -0.41, indicating a unique financial structure. With a price-to-book ratio of 6.05 and no dividend yield, Twist Bioscience Corp. continues to navigate the complexities of the biotechnology industry while marking this notable achievement in its stock performance.